TELMISARTAN AND AZELNIDIPINE QUANTIFICATION EMPLOYING HPLC STRATAGEM; STABILITY INVESTIGATION ON TELMISARTAN AND AZELNIDIPINE

Authors

  • K. V. L. D. SPANDANA Department of Pharmacy, University College of Technology, Osmania University, Hyderabad, India https://orcid.org/0000-0002-6772-7242
  • N. J. P. SUBHASHINI Department of Pharmacy, University College of Technology, Osmania University, Hyderabad, India

DOI:

https://doi.org/10.22159/ijap.2022v14i1.43321

Keywords:

Telmisartan, Azelnidipine, Hypertension, Stability investigation, HPLC

Abstract

Objective: The focus of our research was to create a fairly sensitive HPLC stratagem for determining telmisartan (TLM) and azelnidipine (AEL) in bulk and tablet types. 

Methods: Analysis of TLM and AEL was performed on a “C18 Kromasil stationary column (5 µm, 250 mm × 4.6 mm)”. The mobile phase was made of 0.1M NaH2PO4 solution (pH 3.5) and methanol at a comparative volume ratio of 50% each. The analysis of TLM and AEL was isocratic, with the flow velocity adjusted at 1.0 ml/min and indeed the TLM and AEL analysis was done at 256 nm using a PDA devise sensor. TLM and AEL were stressed with acid, peroxide, dry heat, alkali, and sun light induced settings.

Results: The retention/elution periods for the TLM and AEL was observed at 2.225 min and 3.178 min, respectively. The HPLC stratagem developed have a straight-line relation with relative concentrations in the ranges of 20 - 60 µg/ml for TLM and 4 - 12 µg/ml for AEL.  The LOQ’s for TLM and AEL were 0.2516 μg/ml and 0.0871 μg/ml, respectively. The validation investigational findings done for TLM and AEL with the established sensitive HPLC stratagem were passed out in conformity with the ICH standards.

Conclusion: The established sensitive HPLC stratagem was shown as competent for the quality check of bulk samples of TLM and AEL throughout batch release as well as in course of TLM and AEL stability investigations.

Downloads

Download data is not yet available.

References

Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, Galli E. Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother 2011; 12:2719-35.

Hwang YJ, Park JH, Cho DH. Activation of AMPK by Telmisartan Decreases Basal and PDGF-stimulated VSMC Proliferation via inhibiting the mTOR/p70S6K Signaling Axis. J Korean Med Sci 2020; 35:e289.

Cho DH. Telmisartan inhibits nitric oxide production and vessel relaxation via protein phosphatase 2a-mediated endothelial NO synthase-Ser1179 dephosphorylation. J Korean Med Sci 2019; 34:e266.

Chen BL, Zhang YZ, Luo JQ, Zhang W. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Ther Clin Risk Manag 2015; 11:309-18.

Bagheri M, Jahromi BM, Mirkhani H, Solhjou Z, Noorafshan A, Zamani A, Amirghofran Z. Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats. J Surg Res 2011; 169:e101-7.

Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007;333:321-6.

Telmisartan + Azelnidipine, 1 mg.com. Accessed on July 2021, Available at: https://www.1mg.com/generics/telmisartan-azelnidipine-509412

Yuvasri S, Murugan S, Vetrichelvan T. First- order derivative and UV-spectrophotometric methods for simultaneous determination of telmisartan and azelnidipine in bulk and tablet dosage form. Eur J Biomed Pharm Sci 2021;8:290-4.

Kumar M, Chandra U, Garg A, Gupta P. A Stability Indicating RP-HPLC Method Validation for simultaneous estimation of Azelnidipine and Telmisartan in a fixed-dose combination. Int J Pharm Sci Drug Res 2021;13:288-94.

Kishore K, Somasekhar RK. Method development and validation for the simultaneous estimation of azelnidipine and telmisartan in pharmaceutical formulation by high performance liquid chromatography. Bull Env Pharmacol Life Sci 2021;10:19-27.

Parikh MB, Pankti Dalwadi, Neetu Dharu. Stability indicating RP-HPLC method development and validation for the simultaneous estimation of telmisartan and azelnidipine in tablet dosage form. Int J All Res Ed Sci Method 2021; 9:1082-90.

International conference on the harmonization. ICH Stability testing of new drug substances and products Q1A (R2); 2003.

International conference on the harmonization. ICH harmonized tripartite guideline. Validation of analytical procedures: Text and methodology Q2(R1); 2005.

Azim Md S, Mitra M, Parminder SB. HPLC method development and validation: a review. Int Res J Pharm2015; 4:39-46.

Sonawane S, Jadhav S, Rahade P, Chhajed S, Kshirsagar S. Development and validation of stability-indicating method for estimation of chlorthalidone in bulk and tablets with the use of experimental design in forced degradation experiments. Scientifica (Cairo) 2016; 2016:4286482.

Blessy M, Ruchi DP, Prajesh NP, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—A review. J Pharm Anal 2014; 4:159-65.

Bakshi M, Singh S. Development of validated stability-indicating assay methods--critical review. J Pharm Biomed Anal 2002; 28:1011-40.

Published

22-11-2021

How to Cite

SPANDANA, K. V. L. D., & SUBHASHINI, N. J. P. (2021). TELMISARTAN AND AZELNIDIPINE QUANTIFICATION EMPLOYING HPLC STRATAGEM; STABILITY INVESTIGATION ON TELMISARTAN AND AZELNIDIPINE. International Journal of Applied Pharmaceutics, 14(1). https://doi.org/10.22159/ijap.2022v14i1.43321

Issue

Section

Original Article(s)